Virtual Library
Start Your Search
Tomohide Sugiyama
Author of
-
+
P2.09 - Pathology (Not CME Accredited Session) (ID 958)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.09-14 - The Detection of EGFR Gene Mutation from Washing Solution of Devices used for the Bronchoscopic Examination (ID 12836)
16:45 - 18:00 | Author(s): Tomohide Sugiyama
- Abstract
Background
The detection of epidermal growth factor receptor (EGFR) gene mutation is necessary for selection of lung cancer treatment. Recently, biopsy specimens are used in many genomic and immunohistochemical examination methods to select the treatment policy, so it is important not to waste valuable cancer cell samples. For detection of EGFR gene mutation we examine the washing solution of devices used for the bronchoscopic examination in order to solve the issue. In this report, we investigate the detection ratio of EGFR mutation using this cytological sample.
a9ded1e5ce5d75814730bb4caaf49419 Method
A total of 336 washing solution samples from lung cancer patients were examined for EGFR gene mutation testing in the period between November 2010 and October 2017. 328 cases of 336 excepting 8, which were carried out as re-biopsy, were surveyed in this examination. After the regular biopsy or scraping method, all devices were washed with 10ml saline liquid. Half volume of washing solution was used for regular cell examination to detect cancer cells. Only if a sufficient amount of non-small cancer cells were observed from it, the other volume was submitted for EGFR mutation examination. Final diagnosis was decided by histological specimen. Presence or absence of EGFR mutation and their types were observed from 328 samples retrospectively.
4c3880bb027f159e801041b1021e88e8 Result
Histological diagnosis of all 328 biopsy specimens are as follows; 200 Adenocarcinoma (AD), 100 Squamous cell carcinoma (SQ), 13 non-small cell lung carcinoma(NSCLC), 3 adenosquamous cell carcinoma(ADSQ), 7 high grade neuroendocrine carcinoma (HGNEC), and 5 others. The detection number of EGFR mutation from AD, SQ, ADSQ and NSCLC are 65, 4, 2, and 3 respectively. There is no EGFR mutation from remaining histology cases. In all of 74 EGFR mutation positive cases, Exon 19 deletion was detected in 33 cases (45%) and Exon 21 L858R was detected in 33 cases (45%).
8eea62084ca7e541d918e823422bd82e Conclusion
The detection rate of EGFR gene mutation from washing solution of devices is 33% (65/200) in AD and 4% (4/100) in SQ. These results are approximate to previous reports. Consequently, it is acceptable to use this method to investigate EGFR gene mutation of non-small lung cancer patients. Furthermore, it is an advantage that we can carry out an EGFR mutation test using this method with a cytology sample earlier than a method with a histology sample.
6f8b794f3246b0c1e1780bb4d4d5dc53
-
+
P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
-
+
P3.01-43 - Predictive Value of Computed Tomography Characteristics for Nivolumab Response in Pretreated Non-Small Cell Lung Cancer (ID 13054)
12:00 - 13:30 | Author(s): Tomohide Sugiyama
- Abstract
Background
The efficacy and safety of nivolumab for the treatment of pretreated non-small cell lung cancer (NSCLC) have been established. We conducted a retrospective multicenter trial to determine the significance of computed tomography (CT) morphologic characteristics as a predictor of nivolumab efficacy for advanced NSCLC patients.
a9ded1e5ce5d75814730bb4caaf49419 Method
From April 2013 to March 2017, 78 pretreated NSCLC patients were enrolled. Our radiologist assessed the following tumor characteristics on CT before nivolumab treatment; interstitial septal thickening, peritumoral ground-glass opacity, spiculated margin, air bronchogram, cavity or necrosis, adjacent organ invasion, bulky lymph node (≥ 2.5 cm), and accumulation of small lymph nodes. After nivolumab treatment, objective response rate (ORR), disease control rate (DCR) and progression free survival (PFS) were analyzed with logistic regression and Cox proportional hazards regression models. Patient and CT morphologic characteristics were retrospectively analyzed. Significant parameters identified by univariate analysis were included in a multiple analysis.
4c3880bb027f159e801041b1021e88e8 Result
Of the 78 patients, 60 (77%) were male, and 72 (92%) patients were of performance status 0 to 1. Heavy smoking was related to higher ORR than light or never smoking (28% vs 0%, p=0.01)．No morphologic characteristics were related to ORR or DCR. Interstitial septal thickening was significantly associated with shorter PFS (p=0.015, 77 vs 126 days). Adjacent organ invasion was also significantly associated with shorter PFS (p=0.047, 72 vs 118 days). However, they were not found to be significant on multivariate analysis.
8eea62084ca7e541d918e823422bd82e Conclusion
Interstitial septal thickening and adjacent organ invasion may be negative prognostic factors of nivolumab treatment for NSCLC.
6f8b794f3246b0c1e1780bb4d4d5dc53
